Noise deafness prevention composition

Oral administration of NMN before noise exposure significantly reduces noise-induced hearing loss by suppressing hearing threshold deterioration, addressing the gap in existing research on oral prevention methods.

JP2024156318AInactive Publication Date: 2024-11-06MEIJI HOLDINGS
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2023070682
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-04-24
Publication Date
2024-11-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing research has not adequately addressed the prevention of noise-induced hearing loss through oral administration of nicotinamide mononucleotide (NMN), despite its potential efficacy in preventing hearing loss caused by noise exposure.

Method used

Oral administration of nicotinamide mononucleotide (NMN) to subjects 14 days or more before noise exposure significantly reduces noise-induced hearing loss by suppressing hearing threshold deterioration.

Benefits of technology

NMN effectively prevents noise-induced hearing loss by maintaining hearing ability within specific frequency ranges, with sound pressure threshold differences minimized through oral ingestion.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024156318000001
    Figure 2024156318000001
  • Figure 2024156318000002
    Figure 2024156318000002
  • Figure 2024156318000003
    Figure 2024156318000003
Patent Text Reader

Abstract

To provide a composition which has a preventive effect on noise deafness.SOLUTION: A noise deafness prevention composition which is a composition for prevention of noise deafness contains nicotinamide mononucleotide (NMN) as an active component. The noise deafness is deafness induced by a load of noise at an acoustic pressure of 100 dB over 1 or more hours or noise equivalent to the noise. The composition is orally administered to a subject 14 days or more before the load of the noise.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a composition for preventing noise-induced hearing loss. [Background technology]

[0002] Noise exposure is one of the main causes of hearing loss in mammals, and hearing loss caused by noise exposure (noise stress) is called "noise-induced hearing loss." Noise-induced hearing loss develops due to damage to the inner ear, cochlear nerve, brain, etc., and is particularly caused by damage to the hair cells in the cochlea, which are responsible for converting sound stimuli into electrical nerve signals. Damaged hair cells do not regenerate, making it difficult to restore hearing, and prevention is particularly important for noise-induced hearing loss.

[0003] Conventionally, for noise-induced hearing loss, for example, JP2015-524408A (Patent Document 1) describes a method for preventing or treating hearing loss by administering an effective amount of nicotinamide riboside (NR) to a mammal. In addition, for example, China Patent Application Publication No. 105535009 (Patent Document 2) describes a drug or health food that contains nicotinamide mononucleotide (NMN) and prevents and treats hearing loss, and describes that the preventive effect against noise-induced hearing loss was evaluated by intraperitoneal administration. However, research focusing on the prevention of noise-induced hearing loss by oral administration has not yet been conducted sufficiently. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] Special Publication No. 2015-524408 [Patent Document 2] China Patent Application Publication No. 105535009 Summary of the Invention [Problem to be solved by the invention]

[0005] The present invention has been made in consideration of the problems associated with the above-mentioned conventional technology, and aims to provide a composition having a preventive effect against noise-induced hearing loss, which is a decrease in hearing ability due to noise exposure. [Means for solving the problem]

[0006] In order to achieve the above object, the present inventors have conducted extensive research and searched for an ingredient effective in preventing noise-induced hearing loss. As a result, they have newly discovered that by orally administering nicotinamide mononucleotide (NMN) to mice prior to noise stress, the hearing loss caused by noise stress is significantly reduced when NMN is not administered, whereas the decrease in hearing loss caused by noise stress can be significantly suppressed when NMN is administered. In other words, they have newly discovered that nicotinamide mononucleotide has a preventive effect against noise-induced hearing loss. Thus, it has become clear that by orally administering (including ingestion) a composition containing nicotinamide mononucleotide as an active ingredient to a subject, noise-induced hearing loss can be particularly prevented, and the present invention has been completed. The aspects of the present invention obtained based on such findings are as follows. [1] A composition for preventing noise-induced hearing loss, Contains nicotinamide mononucleotide (NMN) as an active ingredient. The noise-induced hearing loss is caused by noise with a sound pressure of 100 dB for one hour or more or an equivalent noise load, and The subject is orally administered the test substance at least 14 days prior to the noise challenge. A composition for preventing noise-induced hearing loss. [2] The composition for preventing noise-induced hearing loss described in [1], wherein in the subject, the difference (day1-pre) between the sound pressure threshold (pre(dB SPL)) measured in an ABR test in a frequency range of 32 kHz before the noise load and the sound pressure threshold (day1(dB SPL)) measured in an ABR test in a frequency range of 32 kHz one day after the noise load is 45 dB SPL or less. [3] A composition for preventing noise-induced hearing loss according to [1] or [2], which is a food or drink composition, a pharmaceutical composition, or a quasi-drug composition. [4] The composition for preventing noise-induced hearing loss according to any one of [1] to [3], wherein the dosage for humans is 0.01 to 500 mg of nicotinamide mononucleotide per kg of body weight per day. [5] Use of nicotinamide mononucleotide (NMN) for the prevention of noise-induced hearing loss, The noise-induced hearing loss is caused by noise with a sound pressure of 100 dB for one hour or more or a noise load equivalent thereto, The use is orally administered to a subject for at least 14 days prior to said noise challenge. [6] Use of nicotinamide mononucleotide (NMN) for the manufacture of a composition for preventing noise-induced hearing loss, The noise-induced hearing loss is caused by noise with a sound pressure of 100 dB for one hour or more or a noise load equivalent thereto, The use is orally administered to a subject for at least 14 days prior to said noise challenge. [7] It is a method to prevent noise-induced hearing loss. The noise-induced hearing loss is caused by noise with a sound pressure of 100 dB for one hour or more or a noise load equivalent thereto, The method includes orally administering an effective amount of nicotinamide mononucleotide (NMN) to the subject from 14 days or more prior to the noise challenge. method. Effect of the Invention

[0007] According to the present invention, it is possible to provide a composition having a preventive effect against noise-induced hearing loss, which is a condition in which hearing is reduced due to noise stress. In addition, since the composition of the present invention can be provided as a food or drink composition, it is easy to administer orally by ingestion and easy to form a habit. [Brief description of the drawings]

[0008] [Figure 1]FIG. 1 is a schematic diagram showing the administration period, noise load, and ABR test schedule in the administration test of Test Example 1. [Figure 2A] 1 is a graph showing the average sound pressure threshold (dB SPL) and standard error at each ABR test time (day: -15, 1, 7, 14) for each group, measured in the ABR test of Test Example 1. [Figure 2B] 1 is a graph showing the sound pressure threshold difference (ΔdB SPL) and its standard error, obtained by subtracting the sound pressure threshold before administration (day: -15) from the sound pressure threshold 1, 7, and 14 days (day: 1, 7, 14) after noise load for each group, measured in the ABR test of Test Example 1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] The present invention will be described in detail below based on preferred embodiments thereof.

[0010] <Composition for preventing noise-induced hearing loss> The present invention provides a composition for preventing noise-induced hearing loss, which contains nicotinamide mononucleotide as an active ingredient (sometimes referred to in this specification as a "composition for preventing noise-induced hearing loss" or simply as the "composition of the present invention").

[0011] The active ingredient contained in the composition for preventing noise-induced hearing loss of the present invention is nicotinamide mononucleotide (sometimes referred to as "NMN" in this specification). The present inventors have found that nicotinamide mononucleotide has a preventive effect against hearing loss caused by noise load in particular, and exerts an excellent preventive effect against noise-induced hearing loss.

[0012] The nicotinamide mononucleotide according to the present invention refers to β-nicotinamide mononucleotide, also abbreviated as NMN. β-nicotinamide mononucleotide is a nucleotide that is converted in vivo from nicotinamide and nicotinamide riboside to nicotinamide adenine dinucleotide (NADH, NAD +Nicotinamide adenine dinucleotide is an intermediate metabolite in the conversion of nicotinamide to nicotinamide adenine dinucleotide. Nicotinamide adenine dinucleotide is known to play a central role in dehydrogenation reactions in living organisms as an oxidation-reduction coenzyme.

[0013] The nicotinamide mononucleotide according to the present invention may be in a free form, a hydrate or a salt form, and in the present specification, the term "nicotinamide mononucleotide" includes any of these. The salt is not particularly limited as long as it does not inhibit the effects of the present invention, and may be a food or medicament acceptable salt, more specifically, for example, a salt with an organic acid (e.g., acetic acid, tartaric acid, fatty acid, etc.), an inorganic acid (e.g., hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, perchloric acid, etc.), an inorganic base (e.g., potassium, sodium, zinc, etc.), etc., and may be one or a combination of two or more of these salts. The form of the nicotinamide mononucleotide according to the present invention may be appropriately selected depending on the form of the composition, the method of administration, etc.

[0014] The origin of the nicotinamide mononucleotide according to the present invention is not particularly limited, and can be obtained, for example, from materials or foods (meat, milk, vegetables, crustaceans (shrimp, crab), mushrooms, etc.) by a conventionally known method such as squeezing, concentrating, purifying, precipitating, and extracting, or a method similar thereto. The nicotinamide mononucleotide according to the present invention may be produced using a microorganism, such as a fermented product of lactic acid bacteria, or may be chemically synthesized. Furthermore, commercially available products (e.g., β-nicotinamide mononucleotide manufactured by Sigma Aldrich, Tokyo Chemical Industry Co., Ltd., or Oriental Yeast Co., Ltd., etc.) may be appropriately obtained.

[0015] In the composition of the present invention, the content of nicotinamide mononucleotide (free form equivalent, the same applies below) is not particularly limited because it is appropriately adjusted depending on the form of the composition, the dosage, the purpose and method of administration, etc., and can be 0.001 to 100% by mass based on the total mass of the composition, but for example, when the composition of the present invention is a food or drink composition, it is more preferably 0.01 to 10% by mass, and even more preferably 0.01 to 1% by mass. Furthermore, for example, when the composition of the present invention is a pharmaceutical composition or a quasi-drug composition, it is more preferably 0.01 to 10% by mass.

[0016] The composition of the present invention may further contain other ingredients acceptable for food or pharmaceutical use in addition to nicotinamide mononucleotide, so long as the effects of the present invention are not inhibited. The other ingredients are not particularly limited, but include, for example, water, lipids, sugars, sugar alcohols, minerals, vitamins, proteins, peptides, amino acids, organic acids, lactic acid bacteria (Lactobacillus, Bifidobacterium, etc.), yeast, processed products of the lactic acid bacteria and / or yeast (crushed products, heat-treated products, etc.), fermented products of the lactic acid bacteria and / or yeast, formulation auxiliary agents, and other active ingredients other than nicotinamide mononucleotide.

[0017] The lipid is not particularly limited, but more specific examples thereof include natural fats and oils such as soybean oil, corn oil, palm oil, perilla oil, canola oil, safflower oil, sunflower oil, sesame oil, rice oil, grape seed oil, fish oil, safflower oil, rapeseed oil, and peanut oil; and synthetic fats and oils such as medium-chain triglycerides (MCT) having about 6 to 12 carbon atoms.

[0018] The saccharides are not particularly limited, but more specific examples include starch, dextrin, maltodextrin, fructooligosaccharides, galactooligosaccharides, lactosaccharose, lactulose, inulin, maltose, sucrose, glucose, and cyclodextrin.

[0019] The sugar alcohols are not particularly limited, but more specific examples include sweeteners such as sorbitol, mannitol, maltitol, erythritol, reduced starch syrup, and reduced palatinose.

[0020] The minerals are not particularly limited, but more specifically include calcium, magnesium, sodium, potassium, phosphorus, iron, manganese, copper, zinc, iodine, zinc, selenium, chromium, and molybdenum.

[0021] The vitamins include, but are not limited to, vitamins A, B1, B2, B5, B6, B7, B9, B12, C, D, E, and K.

[0022] The formulation auxiliary is not particularly limited, but more specific examples thereof include solvents, dispersants, emulsifiers, thickeners, thickening stabilizers, gelling agents, surfactants, buffers, stabilizers, excipients, binders, disintegrants, lubricants, flavorings, dissolution aids, suspending agents, coating agents, carriers (solid carriers, liquid carriers such as water), preservatives, fragrances, colorants, and pH adjusters.

[0023] The other active ingredients besides nicotinamide mononucleotide are not particularly limited, but more specific examples include dietary fiber (resistant dextrin, etc.), fruits and vegetables and processed products thereof, animal and plant extracts, naturally occurring polymers (collagen, hyaluronic acid, chondroitin, etc.), and the like.

[0024] The other components may be one type or two or more types. When these other components are contained, the content of the other components is not particularly limited and can be appropriately adjusted depending on the form of the composition, the dosage, the purpose and method of administration, etc.

[0025] The composition of the present invention is administered orally, and can be prepared as an oral composition according to the administration form. The composition of the present invention can be prepared as a pharmaceutical composition, a quasi-drug composition, a food and drink composition, or a feed composition according to the purpose, subject, method, dosage, etc. of administering the composition.

[0026] The pharmaceutical composition and quasi-drug composition according to the present invention can be, for example, a preparation, the form of which is not particularly limited, and examples thereof include solid preparations such as tablets, pills, granules, powders, powders, and capsules; liquid preparations such as general liquid preparations, suspensions, emulsions, and syrups; jellies, etc. The preparations can be produced, for example, by adding one or more of the formulation auxiliary agents to nicotinamide mononucleotide, and further adding one or more of the other components as necessary, by a known method or a method similar thereto.

[0027] The form of the food and drink composition according to the present invention is not particularly limited, and examples thereof include solid forms such as bars, liquid forms such as beverages and liquid foods, pastes, semi-liquid forms, gels (jelly forms), gelled oils and fats (semi-solid oils and fats), powders, etc. The food and drink compositions can also be administered to patients, the elderly, infants, etc. as liquid foods, powdered liquid foods, nutritional pastes, oral nutrients, beverages, gelled foods, etc.

[0028] Examples of the food and drink composition according to the present invention include, but are not limited to, beverages (tea, carbonated beverages, cocoa, coffee, lactobacillus beverages, soy milk beverages, fruit and vegetable juice beverages, soft drinks, nutritional beverages, alcoholic beverages, etc.), processed foods (chocolate, gum, gummy candy, jelly, baked goods (bread, cake, cookies, biscuits, etc.), candy, etc.), dairy products (modified milk powder (powdered milk, etc.), modified milk, milk beverages, fermented milk, yogurt, ice cream, cheese, cream, butter, margarine, condensed milk, etc.), seasonings (sauces, soups, dressings, mayonnaise, mayonnaise-type seasonings, cream, etc.), supplements, edible oils, and functional edible oils and fats. Such food and drink compositions can be produced, for example, by a method of blending the nicotinamide mononucleotide according to the present invention with an existing food and drink, or its raw materials, or an intermediate product in the manufacturing process. The nicotinamide mononucleotide to be blended in this case may be in the form of the pharmaceutical composition or quasi-drug composition.

[0029] The food and drink composition according to the present invention may be, for example, a general food, a health food, a functional food, a health functional food (e.g., a food for specified health uses, a nutrient functional food, a nutritional supplement, a food with functional claims, etc.), a food for special dietary uses (e.g., a food for infants, a food for pregnant women, a food for the sick, etc.), a medical food (a food prescribed under the supervision of a doctor as defined by the U.S. Food and Drug Administration (FDA) and the Orphan Drug Act), a therapeutic food (a food that serves the purpose of treatment and is prepared based on a menu prepared by a nutritionist or the like in accordance with a diet prescription prepared by a doctor), or a dietary therapy food. The food and drink composition may be labeled with the action and efficacy (prevention of noise-induced hearing loss) provided by the nicotinamide mononucleotide according to the present invention.

[0030] The feed composition according to the present invention may be the above-mentioned food and drink composition appropriately modified depending on the purpose, subject, method, dosage, etc. of administration of the feed composition.

[0031] The composition of the present invention is preferably packaged (preferably enclosed) in a packaging container from the time of production to the time of administration. The packaging container is not particularly limited, but examples thereof include wrapping paper, packaging bags, soft bags, tubes, cheer packs, paper containers, cans, bottles, and capsules.

[0032] The composition of the present invention contains the above-mentioned nicotinamide mononucleotide as an active ingredient, and is orally administered to a subject from 14 days or more before noise load. This prevents noise-induced hearing loss in the subject. Therefore, the present invention also provides the use of nicotinamide mononucleotide for preventing noise-induced hearing loss, as well as the use of nicotinamide mononucleotide for producing a composition for preventing noise-induced hearing loss. The composition of the present invention may also be used to improve noise-induced hearing loss, but such use may be excluded.

[0033] The subject may be a human or a non-human mammal, and the non-human mammal may be a mouse, sheep, cow, pig, horse, monkey, dog, cat, rabbit, etc. The subject may be a person for whom the purpose is to prevent the onset of noise-induced hearing loss, but may also be a person who already suffers from noise-induced hearing loss. In the present invention, oral administration also includes the ingestion of the food and drink composition, the feed composition, etc.

[0034] The composition of the present invention is orally administered to the subject from 14 days or more before noise loading (before -14 days, with the day of noise loading being considered as day 0) continuously until the day before the loading day, i.e., for 14 days or more from 14 days or more before the loading. The number of days of administration before the noise loading is preferably at least 7 days or more, and more preferably 14 days or more. There is no particular upper limit to the number of days of administration, but it is preferably 30 days, and more preferably 25 days. In the present invention, "continuously" preferably means every day, and more preferably once to multiple times a day (preferably once) at the dosage below.

[0035] It is also preferred that the composition of the present invention is further administered on the day of and / or after the noise exposure. In this case, the number of days after the noise exposure is preferably between 0 and 30 days, and more preferably between 0 and 14 days (15 days), with the day of noise exposure being counted as day 0.

[0036] The dosage of the composition of the present invention can be appropriately determined for each individual case, taking into consideration the form of the composition, the purpose and method of administration, and the species, age, body weight, sex, medical history, etc. of the subject. Thus, without being particularly limited, for example, the dosage for humans (preferably adults) is preferably 0.01 to 500 mg of nicotinamide mononucleotide (in free form, the same applies below) per kg of subject body weight and per day, more preferably, for example, 1 to 500 mg, 2 to 250 mg, or 10 to 200 mg.

[0037] The noise-induced hearing loss prevented by the composition of the present invention is specifically hearing loss caused by noise with a sound pressure of 100 dB for 1 hour or more, preferably noise with a sound pressure of 110 dB for 2 hours or more, or a noise load equivalent thereto. Examples of noise equivalent to a sound pressure of 110 dB include pianos, music venues, clubs, dog barking, car horns, and construction sites. The upper limit of the noise is, for example, a sound pressure of 110 bB for 3 hours. The frequency of the noise is preferably 8 to 96 kHz.

[0038] The noise-induced hearing loss according to the present invention includes a hearing loss in a frequency range of 17 kHz or more, 20 kHz or more, 23 kHz or more, 25 kHz or more, and 30 kHz or more, and is preferably a hearing loss in a frequency range of 32 kHz or more. The inventors have found that nicotinamide mononucleotide can particularly suppress the hearing loss in such a high frequency range. The upper limit of the frequency range of the hearing loss is, for example, 50 kHz or 96 kHz. These upper and lower limits can be appropriately combined, and the noise-induced hearing loss according to the present invention is more preferably a hearing loss in a frequency range of 17 to 96 kHz, 20 to 96 kHz, 23 to 96 kHz, 25 to 96 kHz, 30 to 96 kHz, 32 to 96 kHz, or 32 to 50 kHz. The composition of the present invention may also be used to prevent hearing loss in the low frequency range (e.g., less than 17 kHz (e.g., 16 kHz or less), less than 20 kHz (e.g., 19 kHz or less), less than 23 kHz (e.g., 22 kHz or less), less than 25 kHz (e.g., 24 kHz or less)), less than 30 kHz (e.g., 29 kHz or less), and less than 32 kHz (e.g., 31 kHz or less)), although such uses may be excluded.

[0039] In the present invention, prevention of noise-induced hearing loss can be confirmed not only by clinically suppressing hearing loss in the above sound range, but also by, for example, maintaining hearing in the above sound range compared to a group that was not administered the composition of the present invention or nicotinamide mononucleotide, a group that was not exposed to noise loading, or the same subject before noise loading.

[0040] More specifically, for example, in the subject, the difference (day1-pre) between the sound pressure threshold (pre(dB SPL)) measured in an ABR test in a frequency range of 32 kHz before the noise load and the sound pressure threshold (day1(dB SPL)) measured in an ABR test in a frequency range of 32 kHz one day after the noise load is preferably 45 dB SPL or less, more preferably 40 dB SPL or less, and even more preferably 35 dB SPL or less. Also, for example, in the subject, the difference (day14-pre) between the sound pressure threshold (pre(dB SPL)) measured in an ABR test in a frequency range of 32 kHz before the noise load and the sound pressure threshold (day14(dB SPL)) measured in an ABR test in a frequency range of 32 kHz 14 days after the noise load is preferably 25 dB SPL or less, more preferably 20 dB SPL or less, and even more preferably 15 dB SPL or less.

[0041] Alternatively, for example, using a group (control group) to which the composition of the present invention or nicotinamide mononucleotide was not administered as a standard, the difference (day1-pre) between the sound pressure threshold (pre(dB SPL)) measured in an ABR test in a frequency range of 32 kHz before the noise load and the sound pressure threshold (day1(dB SPL)) measured in an ABR test in a frequency range of 32 kHz one day after the noise load is preferably 90% or less of (day1-pre) in the control group, more preferably 80% or less, and even more preferably 70% or less. Furthermore, for example, in the subject, the difference (day14-pre) between the sound pressure threshold (pre(dB SPL)) measured by an ABR test in a frequency range of 32 kHz before the noise loading and the sound pressure threshold (day14(dB SPL)) measured by an ABR test in a frequency range of 32 kHz 14 days after the noise loading is preferably 70% or less, more preferably 60% or less, and even more preferably 50% or less, of the control group (day14-pre).

[0042] The ABR test is an Auditory Brainstem Response test, and can be carried out by any known method.Preferably, the method described in the following examples can be mentioned.For humans, for example, electrodes for brainwave are attached to a total of four locations, including the left and right earlobes and head (top and forehead), and sound stimulation is given with a sound pressure range of 10-90 dB and a sound type of 32 kHz tone burst, and the waveform is recorded under the recording conditions of sampling time: 10 ms, sampling rate: 40 kHz, bandpass filter: 1-3000 Hz, and number of additions: 500 times, and the minimum sound pressure at which the waveform is detected can be the sound pressure threshold (dB SPL) in the sound range of 32 kHz.

[0043] <How to prevent noise-induced hearing loss> As described above, administering nicotinamide mononucleotide to the subject can prevent noise-induced hearing loss in the subject. Therefore, the present invention also provides a method for preventing noise-induced hearing loss (hereinafter, sometimes referred to as the "method of the present invention"), which includes a step of orally administering an effective amount of nicotinamide mononucleotide (NMN) to the subject from 14 days or more before the noise load. The method of the present invention can also be a method for preventing each disease or symptom caused by the above-mentioned noise-induced hearing loss.

[0044] In the method of the present invention, nicotinamide mononucleotide can be administered as it is, or more preferably as the composition of the present invention, and is orally administered to the subject. As described above, in the present invention, oral administration also includes ingestion of the food and drink composition, the feed composition, etc.

[0045] In the method of the present invention, the effective amount of nicotinamide mononucleotide is not particularly limited, since it is appropriately determined for each individual case taking into consideration the purpose and method of administration, the species, age, body weight, sex, medical history, etc. of the subject, but like the dosage of the composition of the present invention described above, for example, for humans (preferably adults), the amount of nicotinamide mononucleotide (free form equivalent, the same applies below) per 1 kg of subject body weight and per day is preferably 0.01 to 500 mg, and also preferably 0.5 to 200 mg, 0.5 to 100 mg, or 1 to 50 mg. As described above, administration may be performed once a day or in multiple divided doses. EXAMPLES

[0046] The present invention will be described in more detail below based on examples and comparative examples, but the present invention is not limited to the following examples.

[0047] <Test Example 1> 1. Preparation of Test Compositions β-nicotinamide mononucleotide (NMN, free form) was weighed using an electronic balance and dissolved in a medium (water for injection, manufactured by Otsuka Pharmaceutical Factory, Inc.) to prepare a test composition (Example) with an NMN concentration of 50 mg / mL. In addition, the medium alone (NMN concentration: 0 mg / mL) that did not contain nicotinamide mononucleotide was used as a control composition (Comparative Example).

[0048] 2. Preparation of Mixed Anesthetic Agent A mixed anesthetic was prepared by mixing 2 mL of Ketalar (registered trademark) 500 mg for injection (ketamine hydrochloride, manufactured by Daiichi Sankyo Propharma Co., Ltd.) and 1 mL of Seractal (registered trademark) 2% injection (xylazine hydrochloride, manufactured by Bayer Yakuhin Co., Ltd.).

[0049] 3. Mice Male SPF mice (strain: C57BL / 6J, Charles River Japan) were obtained and firstly, a preliminary breeding period of 8 days was set. During this preliminary breeding period, body weight was measured 3 times, the ABR test described below 4 was performed once, and general condition (whole body observation, excretion state, walking state, etc.) was observed once a day (8 times in total), and mice that showed no abnormalities in body weight transition, ABR test results, or general condition were divided into groups.

[0050] The mice were divided into groups by excluding from the group two mice that had the highest sum of sound pressure thresholds (minimum audible value) at frequencies of 16 kHz, 24 kHz, and 32 kHz in the ABR test during the preliminary breeding period, and then stratified by weight using a computer program (IBUKI, manufactured by Japan Bio Research Center Co., Ltd.).The mice were then randomly divided into two groups of eight mice each, so that the mean weight and variance of each group were approximately equal.

[0051] During the preliminary breeding period and the administration test period described below in 5., the mice were kept in flat-bed plastic cages (width: 175 mm × depth: 245 mm × height: 125 mm) containing environmental enrichment (nesting sheets and autoclaved bedding (Peperclean, manufactured by Japan SLC Co., Ltd.)) in groups of two mice per cage in a breeding room maintained under the following breeding conditions: temperature: 18.0 to 28.0°C (actual value: 22.3 to 24.8°C), humidity: 30.0 to 80.0% RH (actual value: 40.2 to 63.4% RH), light and dark period: 12 hours each (lights on: 6:00 to 18:00), and ventilation rate: 12 times / hour (filtered fresh air).

[0052] During the preliminary rearing period and the administration test period described below in 6, the mice were given solid feed (Lab Diet5053 (PicoLab RodentDiet 20), manufactured by Japan SLC Co., Ltd.) that had been produced within 9 months and were given free access to it in a feeder. In addition, the mice were given tap water in a water bottle and given free access to it.

[0053] 4. ABR (Auditory Brainstem Response) Test In this study, the ABR test was performed as follows. First, the mixed anesthetic prepared in 2. above was subcutaneously administered (amount of administered solution: 2 mL / kg) to the back of the subject mouse using a disposable polypropylene syringe (Terumo Corporation) equipped with a 27G needle (Terumo Corporation) to anesthetize the subject mouse. After anesthesia, a relevant electrode was attached subcutaneously to the head near the outer ear of the test ear (right ear), an indifferent electrode was attached subcutaneously to the parietal area, and an earth electrode was attached subcutaneously to the neck area. The ABR potential was induced from the electrode to a biopotential amplifier (Model: ER-1, Cygnus Technology Inc.), and recorded on a data acquisition and analysis system (PowerLab, Sampling software: LabChart ver.8, ADInstruments) under the following recording conditions: Sampling time: 10 ms, Sampling rate: 40 kHz, Bandpass filter: 1-3000 Hz, and number of additions: 500 times.

[0054] The sound stimulus was given by inserting a Coupler type speaker (Model: ES1spc, Bio Research Center Co., Ltd.) into the right ear canal and applying it from a TDT sound system (ZBus for system3, Tucker-Davis Technologies Inc.) (sound pressure range: 10-90 dB, sound type: 32 kHz Tone burst). For the 32 kHz sound, a 90 dB sound stimulus was first applied to record the ABR waveform, and then the sound pressure was appropriately changed to confirm the maximum sound pressure at which the ABR waveform disappeared and the minimum sound pressure at which the ABR waveform was detected in 5 dB increments. The minimum sound pressure at which the ABR waveform was detected was taken as the sound pressure threshold (dB SPL) for the sound with a frequency of 32 kHz.

[0055] 5. Noise load In this test, the noise load was performed in the following manner. First, the mixed anesthetic prepared in 2 above was subcutaneously administered (amount of administered solution: 2 mL / kg) to the back of the subject mouse using a disposable polypropylene syringe (Terumo Corporation) equipped with a 27G needle (Terumo Corporation) to anesthetize the subject mouse. After anesthesia, a coupler type speaker (Model: ES1spc, Bio Research Center Co., Ltd.) was inserted into the right ear canal, and sound stimulation (sound pressure range: 110 dB, type of sound: octave band noise with a center frequency of 8 kHz) was given for 2 hours from a TDT sound system (ZBus for system3, Tucker-Davis Technologies Inc.).

[0056] 6. Administration test One of the groups of mice divided in 3. above was designated as the "control group" and the other group was designated as the "NMN group". The control group was orally administered the control composition (comparative example) prepared in 1. above at 10 mL / kg (NMN dose: 0 mg / kg), and the NMN group was orally administered the test composition (example) prepared in 1. above at 10 mL / kg (NMN dose: 500 mg / kg). Administration was performed once a day for 29 days. The mice in each group were subjected to noise loading as described in 5. above once on the 14th day (day: 0) from the start of administration (day: -14). Before administration (at 8 weeks of age, pre, day: -15), 1 day (day: 1), 7 days (day: 7), and 14 days (day: 14) after the noise loading day (day: 0), the ABR test described in 4. above was performed to measure the sound pressure threshold (dB SPL). A schematic diagram of the treatment period, noise challenge, and ABR testing schedule is shown in Figure 1.

[0057] 7. Analysis of ABR test results For the sound pressure threshold at a frequency of 32 kHz measured in the ABR test during the administration test in 6. above, the average value and standard error were calculated for each ABR test time (day: -15, 1, 7, 14) for each group (control group (n=8), NMN group (n=8)). Figure 2A shows the average sound pressure threshold (dB SPL) at each ABR test time (day) for each group, with the standard error ((dB SPL) ± SE) indicated by a bar. Figure 2B shows the average value obtained by subtracting the sound pressure threshold before administration (day: -15) from each sound pressure threshold 1, 7, and 14 days after noise exposure (day: 1, 7, 14) as the sound pressure threshold difference (ΔdB SPL), with the standard error ((ΔdB SPL) ± SE) indicated by a bar.

[0058] As shown in Figure 2A, in both the control group and the NMN group, the sound pressure threshold increased significantly due to noise exposure (p value < 0.01 by Wilcoxon signed rank test, "**" in Figure 2A). However, as shown in Figure 2B, the amount of increase was significantly smaller in the NMN group than in the control group (p value < 0.05 by Wilcoxon signed rank test, "#" in Figure 2B). Therefore, it was confirmed that administration of NMN before noise exposure significantly suppressed, i.e., prevented, noise-induced hearing loss. Each Wilcoxon rank sum test was performed using a statistical program (SAS system, manufactured by SAS Institute Japan, Ltd.). [Industrial Applicability]

[0059] As described above, according to the present invention, it is possible to provide a composition having a preventive effect against noise-induced hearing loss.

Claims

1. A composition for preventing noise-induced hearing loss, Contains nicotinamide mononucleotide (NMN) as an active ingredient. The noise-induced hearing loss is caused by noise with a sound pressure of 100 dB for one hour or more or a noise equivalent thereto, and The subject is orally administered 14 days or more prior to the noise challenge. A composition for preventing noise-induced hearing loss.

2. 2. The composition for preventing noise-induced hearing loss according to claim 1, wherein the difference (day1-pre) between the sound pressure threshold (pre (dB SPL)) measured in an ABR test in a frequency range of 32 kHz before the noise loading and the sound pressure threshold (day1 (dB SPL)) measured in an ABR test in a frequency range of 32 kHz one day after the noise loading is 45 dB SPL or less.

3. The composition for preventing noise-induced hearing loss according to claim 1, which is a food or drink composition, a pharmaceutical composition, or a quasi-drug composition.

4. A composition for preventing noise-induced hearing loss described in any one of claims 1 to 3, characterized in that the dosage for humans is 0.01 to 500 mg of nicotinamide mononucleotide per kg of body weight per day.

Citation Information

Patent Citations

  • Drug or health care product for preventing and treating hearing loss

    CN105535009A

  • Nicotinamide riboside for treating hearing loss

    JP2015524408A